Dermatology and Therapy最新文献

{"title":"Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension.","authors":"Julie Barberio, Venkatesh Harikrishnan, Shiyao Gao, Andrea Marcus, Sarah-Jo Sinnott","doi":"10.1007/s13555-026-01859-y","DOIUrl":"10.1007/s13555-026-01859-y","url":null,"abstract":"<p><strong>Introduction: </strong>Selectively prescribing new medications to patients with severe disease can lead to channeling bias in observational studies. Potential for channeling upon label extension has not been described. The objective of this study was to describe dupilumab-treated patients with moderate-to-severe atopic dermatitis (AD) at initial United States Food and Drug Administration (FDA) approval for adults (March 2017) and at label extensions to adolescents (March 2019), children (May 2020), and young children (June 2022).</p><p><strong>Methods: </strong>A cross-sectional study was conducted using Optum's de-identified Clinformatics® Data Mart Database to describe baseline characteristics of patients with AD in the US who initiated dupilumab within 6 months of FDA approval or label extension.</p><p><strong>Results: </strong>Dupilumab-treated patients with AD at initial approval, versus the most recent label update, had a higher prevalence of comorbid Type 2 inflammatory diseases (e.g., asthma: 33% versus 22%), a larger proportion of prior systemic immunosuppressant use (31% versus 5%), and more frequent dermatologist visits in the previous year (mean 6.1 versus 3.1 visits). Newly licensed adolescents and children had a greater burden of atopic comorbidities and a different pattern of prior AD treatment than adults.</p><p><strong>Conclusion: </strong>Patients initiating dupilumab in March 2017 had markers of high disease burden, consistent with channeling. As the label extended, the population shifted toward the indicated moderate-to-severe phenotype. Channeling trends were difficult to assess given the well-established differences in comorbidities and treatment patterns in pediatric AD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4475-4486"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study.","authors":"Anthony Bewley, Andreas Pinter, José Luis López Estebaranz, Jordi Galván, Víctor Sapena, Volker Koscielny","doi":"10.1007/s13555-026-01884-x","DOIUrl":"10.1007/s13555-026-01884-x","url":null,"abstract":"<p><strong>Introduction: </strong>Scalp psoriasis is often associated with poor adherence to topical therapy. A novel formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion (CAL/BDP PAD-cream) showed improved outcomes and satisfaction in the PRO-SCALP study, particularly in patients with high adherence. We evaluated how adherence to CAL/BDP PAD-cream influences patients- and clinicians-reported outcomes and treatment preferences in mild-to-moderate scalp psoriasis under real-life conditions in Europe.</p><p><strong>Methods: </strong>PRO-SCALP patients reported their adherence level using a visual analogue scale (VAS). Outcomes were compared between low- and high-adherence subgroups.</p><p><strong>Results: </strong>Among 252 patients, 59.9% reported high adherence (VAS 80-100). Older patients and those with moderate disease reported high adherence (both p < 0.05). High-adherent patients reported higher scores in the Treatment Satisfaction Questionnaire for Medication Version 9, for Convenience of use (p = 0.0019) and Global Satisfaction (p = 0.0166) domains, and in the Psychosocial Effects of Scalp Psoriasis Questionnaire (p = 0.0004) at week 8. Both adherence subgroups showed significant reductions in the scalp Worst Itch Numeric Rating Scale (WI-NRS), scalp-modified Psoriasis Area and Severity Index (S-mPASI), and Scalpdex scores (all p < 0.0001 vs. baseline), although high-adherent patients achieved greater improvements in WI-NRS (p < 0.0001), S-mPASI (p = 0.0153), and the Scalpdex Symptoms domain (p = 0.001) than low-adherent. Each 10% increase in adherence corresponded to a 0.10- and 0.35-point reduction in S-mPASI and WI-NRS (both p < 0.05) at week 8. Scalp-Physician Global Assessment success rates were comparable in low- vs. high-adherence subgroups (65.0% vs. 70.5%; p = 0.3633). Sleep quality improved significantly in both subgroups (p < 0.0001). High adherence was associated with higher Patient Preference Questionnaire scores (p = 0.0012), better Cream Usability Scalp Psoriasis Questionnaire ratings (p = 0.0455) and greater product consumption (p < 0.0001), despite similar once-a-day usage.</p><p><strong>Conclusion: </strong>High adherence to CAL/BDP PAD-cream was associated with greater effectiveness, satisfaction, preference, and QoL. While patients with low adherence still benefited, maximizing adherence is key for optimal real-world outcomes in scalp psoriasis.</p><p><strong>Trial registration number: </strong>ClinicalTrials.gov identifier NCT05811234.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4683-4703"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of \"Ozempic Face\".","authors":"Saroja Rao, Isabella Midura, Kathyana P Santiago Mangual, Leon I Igel, Katherine H Saunders, Jocelyn Carter, Jenny E Murase, Arianne Shadi Kourosh","doi":"10.1007/s13555-026-01882-z","DOIUrl":"10.1007/s13555-026-01882-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;With the surge in use of glucagon-like peptide 1-receptor agonists (GLP-1RAs) for weight management, \"Ozempic Face,\" one of the dermatologic effects describing facial hollowing, sinking cheeks, and skin laxity, has drawn public attention. While substantial media discourse has surrounded certain dermatologic effects, patient-reported data is needed to more accurately characterize them. This study identifies patient-reported changes in skin, hair, and nails associated with weight management treatment with GLP-1RAs, including the frequency of dermatologic effects relative to weight loss.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Our study was conducted through an IRB-approved, voluntary, anonymous survey developed via collaboration between obesity medicine physicians and dermatologists. The survey was then distributed to patients of a virtual cardio-kidney-metabolic treatment program. Responses (n = 1226) were sorted by the percent body weight lost and categorized by medication regimen (glucagon-like peptide 1-receptor agonists; GLP-1RA, nonGLP-1RA, or combination therapy). Patients reported dermatologic and overall physical changes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Dermatologic effects were reported more frequently with greater weight loss. Of respondents reporting greater than 20% body weight loss, (n = 325) 233 (72%; 95% CI 67-76) reported skin sagging, (n = 325) 170 (52%; 95% CI 47-58) reported hair loss, (n = 325) 163 (50%; 95% CI 45-55) reported decreased facial volume, and (n = 325) 107 (33%; 95% CI 28-38) reported reduced strength. Of respondents reporting 10-20% weight loss, (n = 395) 172 (44%; 95% CI 39-49) reported skin sagging, (n = 395) 119 (30%; 95% CI 26-35) reported hair loss, (n = 395) 147 (37%; 95% CI 33-42) reported decreased facial volume, and (n = 395) 76 (19%; 95% CI 16-23%) reported reduced strength. In comparison, of respondents reporting less than 10% weight loss, only (n = 380) 57 (15%; 95% CI 12-19) reported skin sagging, (n = 380) 65 (17%; 95% CI 13-21) reported hair loss, (n = 380) 48 (13%; 95% CI 10-16) reported decreased facial volume, and (n = 380) 35 (9%; 95% CI 7-13) reported reduced strength. The frequency of adverse patient-reported outcomes increased significantly with increasing percentage of body weight loss. Cochran-Armitage trend testing identified significant positive trends across the &lt; 10%, 10-20%, and &gt; 20% body weight loss categories for skin sagging (Z = 15.22), hair loss (Z = 9.91), decreased facial volume (Z = 10.70), and reduced strength (Z = 7.85), with P values of &lt; 0.001. Among survey respondents on at least one GLP-1RA medication therapy, improvement was reported in certain preexisting inflammatory and hormonally driven skin conditions, including hidradenitis suppurativa (n = 15), 13 (87%; 95% CI 60-98); acanthosis nigricans (n = 12), 9 (75%; 95% CI 43-93); psoriasis (n = 47), 22 (47%; 95% CI 32-62); acne (n = 41), 17 (41%; 95% CI 27-57); eczema (n = 64), 17 (27%; 95% CI 17","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4749-4760"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Evaluation of Cross-linked Sodium Hyaluronate Gel for Injection in Treating Moderate-to-Severe Nasolabial Folds: A Randomized Controlled Evaluator-Blind Non-inferiority Study.","authors":"Xinlyu Huang, Yankun Zhang, Jie Dong, Xiaowei Qin, Shixin Yang, Jun Li, Lanying Qin, Fang Liu","doi":"10.1007/s13555-026-01847-2","DOIUrl":"10.1007/s13555-026-01847-2","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluates a novel lidocaine-premixed hyaluronic acid (HA) gel for nasolabial fold (NLF) correction, addressing pain management and longevity challenges in facial rejuvenation. The aim is to assess the non-inferiority, efficacy, and safety of this investigational HA gel versus an established comparator.</p><p><strong>Methods: </strong>In this multicenter, evaluator-blinded randomized controlled trial (RCT), 324 Chinese adults with moderate-to-severe NLFs (Wrinkle Severity Rating Scale [WSRS] 3-4) received either test product (22 mg/mL HA + 3 mg/mL lidocaine) or control. The primary endpoint was ≥ 1 grade WSRS improvement at 6 months.</p><p><strong>Results: </strong>The test product showed non-inferiority at 6 months (full analysis set [FAS]: 88.27% versus 85.19%, P = 0.392; per‑protocol set (PPS): 91.45% versus 88.24%, P = 0.363), with 95% confidence intervals (CIs) exceeding a -10% margin. Pain scores were comparable at 0.5 h/1 h post-injection (P > 0.05) but higher at 2 h post-touch-up (P < 0.05). Adverse event (AE) rates were similar, with induration/swelling being most common.</p><p><strong>Conclusions: </strong>The lidocaine-premixed HA gel is non-inferior for NLF correction, offering similar safety and efficacy with integrated anesthesia.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4539-4549"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.","authors":"Francesco D'Oria, Sara Di Giulio, Luciano Ibba, Costanza Falcidia, Giulio Foggi, Carlo Alberto Vignoli, Paola Facheris, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Alessandra Narcisi, Mario Valenti","doi":"10.1007/s13555-026-01850-7","DOIUrl":"10.1007/s13555-026-01850-7","url":null,"abstract":"<p><strong>Introduction: </strong>Baricitinib and ritlecitinib are approved targeted therapies for severe alopecia areata (AA), but direct comparative real-world data remain limited. This monocentric retrospective study evaluated the treatment profile, effectiveness, and safety of both agents in routine clinical practice.</p><p><strong>Methods: </strong>We included 160 patients with severe AA, defined by a Severity of Alopecia Tool (SALT) score ≥ 50, treated with baricitinib 4 mg (n = 110) or ritlecitinib 50 mg (n = 50). Clinical outcomes were assessed at baseline, week 16, and week 52; week 104 data were available for baricitinib. The primary endpoint was achieving SALT ≤ 20 at week 52. Secondary outcomes included SALT ≤ 20 at weeks 16 and 104, improvement in eyebrow and eyelash involvement assessed using clinician-reported outcome (ClinRO) measures, treatment discontinuation, and safety.</p><p><strong>Results: </strong>Both treatments were associated with progressive clinical improvement through week 52. SALT ≤ 20 response rates were comparable for baricitinib and ritlecitinib at week 16 (39.6% vs. 36.8%) and increased similarly at week 52 (65.5% vs. 61.5%). Among patients with baseline ClinRO scores ≥ 2, eyelash response was achieved by 40.0% and 41.7% of patients at week 16, increasing to 63.0% and 60.0% at week 52, respectively. Eyebrow response was achieved by 35.1% and 28.6% at week 16 and by 59.4% and 40.0% at week 52, respectively. Discontinuation due to adverse events (AEs) was infrequent in both groups (3.6% vs. 3.1%). Non-severe AEs were more frequent with baricitinib than with ritlecitinib (42.7% vs. 26.0%), mainly driven by weight gain, while no major cardiovascular, thromboembolic, or malignancy-related events were observed.</p><p><strong>Conclusion: </strong>In this real-world retrospective study, baricitinib and ritlecitinib showed comparable effectiveness through week 52 and favorable safety profiles in patients with severe AA, supporting their role as effective targeted therapies in routine clinical practice.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4387-4402"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials.","authors":"Maria Esposito, Juan Manuel Morón-Ocaña, Aditya K Gupta, Jordi Galván, Ayoub Bentohami, Frank Freischläger","doi":"10.1007/s13555-026-01840-9","DOIUrl":"10.1007/s13555-026-01840-9","url":null,"abstract":"<p><strong>Introduction: </strong>Topical therapy plays an essential role in psoriasis management. However, lack of rapid improvement may negatively impact adherence. The calcipotriol and betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology has demonstrated high efficacy, favorable safety, and convenience compared with CAL/BDP gel in phase III trials. This post-hoc analysis aims to assess early treatment response to CAL/BDP PAD-cream at Week (W) 4.</p><p><strong>Methods: </strong>This was a post-hoc pooled analysis of adults with mild-to-moderate psoriasis from two multicenter, investigator-blind, phase III trials (MC2-01-C2 and MC2-01-C7). Patients were randomized 3:1:3 to CAL/BDP PAD-cream (N = 551), PAD-cream vehicle (N = 178), or CAL/BDP gel (N = 542) once daily for 8 weeks. Physician's Global Assessment (PGA) and Subject's Global Assessment (SGA) were assessed at W1 and W4. At W4, early responders were defined as patients achieving PGA controlled disease (i.e., any improvement from baseline to a PGA score of 0-1), while PGA success was defined as a PGA score of 0-1 combined with a minimum 2-point improvement from baseline. SGA controlled disease and SGA success were also assessed. Comparisons between groups were performed by logistic regression models using multiple imputation. Rates of PGA/SGA concordance were assessed by simple percent agreement.</p><p><strong>Results: </strong>At W4, CAL/BDP PAD-cream was associated with a significantly higher proportion of patients achieving early response compared with CAL/BDP gel (32.1% vs 21.4%, P < 0.0001). Differences were already significant at W1 (7.8% vs 4.8%, P = 0.0410). PGA success at W4 was also higher with CAL/BDP PAD-cream than with CAL/BDP gel (23.6% vs 14.8%, P < 0.0001). Rates of SGA controlled disease and success were also statistically significantly higher for CAL/BDP PAD-cream at W4. Concordance between PGA/SGA assessments at W4 was observed in 65.5% (controlled disease) and 69.5% (success) of patients treated with CAL/BDP PAD-cream.</p><p><strong>Conclusion: </strong>CAL/BDP PAD-cream was associated with significantly higher early response rates at W4 than CAL/BDP gel, suggesting earlier clinical improvements.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4719-4728"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry.","authors":"Mark G Lebwohl, Ranga Gogineni, Asif Shaikh, Taylor Blachley, Thomas Eckmann, Alicia Beeghly, Jerry Bagel","doi":"10.1007/s13555-026-01842-7","DOIUrl":"10.1007/s13555-026-01842-7","url":null,"abstract":"<p><strong>Introduction: </strong>Tildrakizumab is an interleukin (IL)-23 p19 inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis. This study assessed tildrakizumab effectiveness and drug survival in real-world patients with prior IL-17 inhibitor (IL-17i) experience.</p><p><strong>Methods: </strong>Patients initiated tildrakizumab (October 2018 to April 2024) at or after enrollment in the PPD™ CorEvitas™ Psoriasis Registry, an independent observational cohort of patients with psoriasis under dermatologist care in North America. Outcomes included drug survival from Kaplan-Meier analysis and changes from baseline in clinician- and patient-reported outcomes, including Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), and patient-reported symptoms at 12 (± 3) months.</p><p><strong>Results: </strong>Of 728 tildrakizumab initiators, 186 (25.5%) had prior IL-17i experience. Their mean age was 56.9 years; 54.3% were female, 137 (73.7%) had prior use of ≥ 2 biologics, including ≥ 1 IL-17i at any time, and 115 (61.8%) used an IL-17i immediately prior to tildrakizumab initiation. Over half (55.4%) had psoriatic arthritis at baseline. Baseline mean PASI was 6.0 (standard deviation [SD] (6.2) and mean DLQI was 7.2 (SD (6.8). The restricted mean tildrakizumab survival time was 27.4 months; 56.8% of initiators were persistent at 12 months. Improvements at 12 months were seen for PASI (mean 2.4, SD 4.8) and DLQI (mean 2.6, SD 5.7); 57.9%, 40.4%, and 38.9% of patients achieved PASI ≤ 3, PASI ≤ 1, and DLQI 0/1, respectively. Improvements in fatigue, skin pain, and itch were also observed.</p><p><strong>Conclusions: </strong>As measured by clinician- and patient-reported outcomes, tildrakizumab was effective in real-world patients in North America with extensive prior biologic experience including immediate prior IL-17i experience. The majority of IL-17i-experienced initiators persisted on treatment for at least 1 year.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4565-4574"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 6-Month Prospective, Open-Label, Randomized Study Showing Increased Hair Growth Rate in Women Using Multi-Targeting Hair Growth Nutraceuticals.","authors":"Rubaina Dang, Raja K Sivamani, Adina Hazan, Isabelle Raymond","doi":"10.1007/s13555-026-01866-z","DOIUrl":"10.1007/s13555-026-01866-z","url":null,"abstract":"<p><strong>Introduction: </strong>Hair thinning is a multifactorial issue affecting women across life stages, frequently associated with reduced linear hair growth rate (LHGR). Hair growth nutraceuticals (HGNs) formulated with variations of a botanical-based multi-targeting complex are designed to address key root causes of hair thinning specific to different life stages. While prior studies have shown improvements in hair growth, quality, and fiber thickness, quantitative changes in LHGR have not been previously evaluated.</p><p><strong>Methods: </strong>This prospective, 6-month study enrolled 180 women aged 18-70 years, assigned to one of four HGNs tailored for women at different life stages and diets. All subjects had self-reported hair thinning, confirmed by the study dermatologist. Participants were assessed at days 0, 90, and 180. Each timepoint included standardized hair clipping followed by objective analysis using Canfield HairMetrix^® 48 h later, which included LHGR, hair counts, and anagen/telogen phase assessment. Self-assessment questionnaires were also completed at each post-baseline timepoint.</p><p><strong>Results: </strong>A total of 150 participants completed the study per protocol. Daily ingestion of the tailored HGNs resulted in statistically significant increases in LHGR at both day 90 and day 180 compared with baseline across all four groups. Anagen hair counts rose significantly across the study duration in all groups, alongside gains in total and terminal hair counts. Total scalp coverage also significantly increased compared with baseline. The changes in hair parameters were corroborated with high agreement regarding improvements in hair parameters in the subject questionnaire.</p><p><strong>Conclusions: </strong>This study demonstrates that consumption of these HGNs is associated with significant improvements in LHGR and other objective hair parameters in women experiencing hair thinning. These findings support the use of targeted HGNs as an effective strategy to enhance hair growth rate and overall hair health across different life stages.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT06376409.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4419-4432"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American Academy of Dermatology 2026 Annual Meeting: Updates in Hidradenitis Suppurativa Medical Management.","authors":"Kenan Kherallah, Claire S Chung, Katrina H Lee, Vivian Y Shi, Jennifer L Hsiao","doi":"10.1007/s13555-026-01849-0","DOIUrl":"10.1007/s13555-026-01849-0","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4241-4248"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology.","authors":"Matthias Augustin, H Chih-Ho Hong, Tiago Torres, Naiem T Issa","doi":"10.1007/s13555-026-01880-1","DOIUrl":"10.1007/s13555-026-01880-1","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4819-4820"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}